Insulin degludec

Biological Activity

Insulin degludec is an ultra-long-acting form of insulin, shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.

Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells.

In vivo, Insulin degludec (5 U/kg; s.c. once daily for 30 days) affects glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia.

Chemical Information

Molecular Weight	6103.97
Formula	C274H411N65O81S6
CAS Number	844439-96-9
Form	Solid
Storage	-20°C, protect from light, dry, sealed

References

[1] Amalia Gastaldelli, et al. Lancet Diabetes Endocrinol. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

[2] Tadej Battelino, et al. Lancet Diabetes Endocrinol. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

[3] Bernhard Ludvik, et al. Lancet. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

[4] Ronald M Goldenberg, et al. Diabetes Obes Metab. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia

[5] Roopa Mehta, et al. Diabetes Obes Metab. Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines